At the time of writing, C4 Therapeutics Inc [CCCC] stock is trading at $3.41, down -4.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CCCC shares have gain 27.24% over the last week, with a monthly amount glided 38.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
C4 Therapeutics Inc [NASDAQ: CCCC] stock has seen the most recent analyst activity on September 15, 2025, when Stephens upgraded its rating to a Overweight but kept the price target unchanged to $6 for it. Previously, Guggenheim started tracking the stock with Buy rating on September 04, 2025, and set its price target to $8. On December 19, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $12 on the stock. Stephens started tracking the stock assigning a Equal-Weight rating and suggested a price target of $4 on November 18, 2024. JP Morgan upgraded its rating to a Neutral but $6 remained the price target by the analyst firm on January 29, 2024. Stifel upgraded its rating to Buy for this stock on December 13, 2023, and upped its price target to $12. In a note dated February 24, 2023, Credit Suisse upgraded a Neutral rating on this stock and revised its target price from $12 to $10.
For the past year, the stock price of C4 Therapeutics Inc fluctuated between $1.09 and $7.14. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $3.41 at the most recent close of the market. An investor can expect a potential return of 75.95% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
According to C4 Therapeutics Inc [NASDAQ:CCCC], the company’s sales were 34.24M for trailing twelve months, which represents an -46.17% plunge. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -3.61%, Pretax Profit Margin comes in at -3.25%, and Net Profit Margin reading is -3.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.54 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that C4 Therapeutics Inc [NASDAQ:CCCC] has a current ratio of 5.06. Further, the Quick Ratio stands at 5.06, while the Cash Ratio is 1.76. Considering the valuation of this stock, the price to sales ratio is 7.09, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Boyle Scott N, Chief Business Officer, that happened on Feb 18 ’25 when 669.0 shares were sold. Chief Business Officer, Boyle Scott N completed a deal on Feb 14 ’25 to sell 490.0 shares. Meanwhile, Director Salter Malcolm bought 13000.0 shares on Nov 18 ’24.
